Salts and compositions useful for treating disease

Abstract

The invention provides a combination or salt of lipoic acid and a compound of formula (I): The combinations and salts are useful for treating diabetes.

1 - 5 . (canceled) 
     
     
         6 . A method for preventing or treating a pathological condition or symptom in a mammal, wherein kappa receptor activity is implicated and antagonism of kappa receptors is desired comprising administering to the mammal an effective amount of:
 a) a lipoic acid salt of a compound of formula (I):   
       
         
           
           
               
               
           
         
         b) a salt of formula (II) or a hydrate thereof: 
       
       
         
           
           
               
               
           
         
         c) a composition comprising a compound of formula (I): 
       
       
         
           
           
               
               
           
         
         and lipoic acid; or 
         d) a composition prepared by combining lipoic acid and a compound of formula (I): 
       
       
         
           
           
               
               
           
         
       
     
     
         7 - 10 . (canceled) 
     
     
         11 . A method for preventing or treating insulin resistance disorder in a mammal, comprising administering to the mammal, an effective amount of a-d as described in  claim 6 . 
     
     
         12 . A method for preventing or treating disease in a mammal, comprising administering to the mammal, an effective amount of a-d as described in  claim 6 , wherein the disease is selected from the group consisting of: (a) diabetes; (b) glucose intolerance; (c) hyperinsulinemia; (d) insulin resistance; (e) diabetic nephropathy; (f) diabetic neuropathy; (g) fatty liver conditions; (h) cardiovascular disease; (i) cachexia in a human subject; (j) atherogenic dyslipidemia; (k) weight management; and (l) impaired glucose tolerance. 
     
     
         13 . A method for preventing or treating metabolic syndrome in a mammal, comprising administering to the mammal, an effective amount of a-d as described in  claim 6 . 
     
     
         14 . A method for treating a pathological condition or symptom in a mammal, wherein kappa receptor activity is implicated and antagonism of kappa receptors is desired comprising administering to the mammal an effective amount of a-d as described in  claim 6 . 
     
     
         15 . A method for treating insulin resistance disorder in a mammal, comprising administering to the mammal, an effective amount of a-d as described in  claim 6 . 
     
     
         16 . A method for treating disease in a mammal, comprising administering to the mammal, an effective amount of a-d as described in  claim 6 , wherein the disease is selected from the group consisting of: (a) diabetes; (b) glucose intolerance; (c) hyperinsulinemia; (d) insulin resistance; (e) diabetic nephropathy; (f) diabetic neuropathy; (g) fatty liver conditions; (h) cardiovascular disease; (i) cachexia in a human subject; (j) atherogenic dyslipidemia; (k) weight management; and (l) impaired glucose tolerance. 
     
     
         17 . A method for treating metabolic syndrome in a mammal, comprising administering to the mammal, an effective amount of a-d as described in  claim 6 . 
     
     
         18 . A method for treating diabetes in a mammal, comprising administering to the mammal, an effective amount of a-d as described in  claim 6 . 
     
     
         19 . A method for treating glucose intolerance in a mammal, comprising administering to the mammal, an effective amount of a-d as described in  claim 6 . 
     
     
         20 . A method for treating hyperinsulinemia in a mammal, comprising administering to the mammal, an effective amount of a-d as described in  claim 6 . 
     
     
         21 . A method for treating diabetic nephropathy in a mammal, comprising administering to the mammal, an effective amount of a-d as described in  claim 6 . 
     
     
         22 . A method for treating a fatty liver condition in a mammal, comprising administering to the mammal, an effective amount of a-d as described in  claim 6   
     
     
         23 . A method for treating cardiovascular disease in a mammal, comprising administering to the mammal, an effective amount of a-d as described in  claim 6 . 
     
     
         24 . A method for treating cachexia in a mammal, comprising administering to the mammal, an effective amount of a-d as described in  claim 6 . 
     
     
         25 . A method for treating atherogenic dyslipidemia in a mammal, comprising administering to the mammal, an effective amount of a-d as described in  claim 6 . 
     
     
         26 . A method for managing weight in a mammal, comprising administering to the mammal, an effective amount of a-d as described in  claim 6 . 
     
     
         27 . A method for treating impaired glucose tolerance in a mammal, comprising administering to the mammal, an effective amount of a-d as described in  claim 6 .